Aksana K. Jones

Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis

Aksana K. Jones, Kevin J. Freise, Suresh Agarwal et al. · The AAPS Journal · 2016 · 102 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +13

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Kevin J. Freise, Aksana K. Jones, Doerthe Eckert et al. · Clinical Pharmacokinetics · 2016 · 63 citations

Medicine, Immunology, Oncology +15

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials

Aksana K. Jones, Eliford Ngaimisi, Mathangi Gopalakrishnan et al. · Clinical Pharmacokinetics · 2020 · 49 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Relationship between venetoclax exposure, rituximab coadministration, and progression‐free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy

Kevin J. Freise, Aksana K. Jones, Rajeev Menon et al. · Hematological Oncology · 2016 · 42 citations

Pharmacy, Immunology, Pharmacotherapy +17

Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients

KJ Freise, Aksana K. Jones, M.E. Verdugo et al. · Clinical Pharmacology & Therapeutics · 2017 · 35 citations

Medicine, Oncology, Pharmacotherapy +17